CHRS
$18.79
Coherus Bio
($.17)
(.90%)
CHRS
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $0.58
Revenue:  $117.04 Mil
Wednesday
Feb 5
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CHRS reports earnings?
Beat
Meet
Miss

Where is CHRS's stock price going from here?
Up
Flat
Down
Stock chart of CHRS
Analysts
Summary of analysts' recommendations for CHRS
Score
Grade
Pivots
Resistance
$19.76
$19.47
$19.21

$18.92

Support
$18.66
$18.37
$18.11
Tweet
Growth
Description
Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.
Peers
Alexion PharmaceuticalsIncyteExact SciencesCharles River Laboratories InternationalExelixisLuminex